Autolus Therapeutics PLC
NASDAQ:AUTL

  • LAST PRICE
    2.8400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.8000/ 5
  • Ask / Lots
    2.8900/ 3
  • Open / Previous Close
    --- / 2.8400
  • Day Range
    ---
  • 52 Week Range
    2.6900
    7.4500
  • Volume
    5

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
AUTL
Autolus Therapeutics PLC
755.7M
-2.4x
---
REPL
Replimune Group Inc
755.0M
-3.6x
---
AVXL
Anavex Life Sciences Corp
764.9M
-18.0x
---
ERAS
Erasca Inc
734.5M
-3.1x
---
TYRA
Tyra Biosciences Inc
777.3M
-9.6x
---
KURA
Kura Oncology Inc
782.3M
-4.3x
---
As of 2024-11-22

Company Information

Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.

Contact Information

Headquarters
The Mediaworks, 191 Wood LaneLONDON, United Kingdom W12 7FP
Phone
203-829-6230
Fax
---

Executives

Chairman of the Board
Michael Bonney
Chief Executive Officer, Executive Director
Christian Itin
Founder, Senior Vice President, Chief Scientific Officer
Martin Pule
Chief Financial Officer, Senior Vice President
Lucinda Crabtree
Chief Operating Officer, Senior Vice President
Christopher Vann

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$755.7M
Revenue (TTM)
$10.1M
Shares Outstanding
266.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.97
EPS
$-1.21
Book Value
---
P/E Ratio
-2.4x
Price/Sales (TTM)
74.9
Price/Cash Flow (TTM)
---
Operating Margin
-2,045.86%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.